Karin Lucas, Ph.D

Title: West Medical Science Liaison Team Lead, Global Medical Affairs Sarepta Therapeutics

Bio: Karin joined the fight to end Duchenne in 2014 when she was recruited to work at Sarepta Therapeutics. As a member of the medical affairs team she contributed to the work resulting in approval of the exon skipping therapies eteplirsen, golodirsen and casimersen and now leads the West MSL team in their work to be a conduit for health care providers and researchers to connect with Sarepta. A protein biochemist by training, Dr. Lucas feels fortunate to be able to combine her passion for science and communication to contribute to the effort to bring novel therapies to neuromuscular patients.

2023 FUTURES: RNA targeted Therapeutics Sessions Part 1

A brief primer on the RNA-targetd therapeutic approach to treating Duchenne, and updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

See more from same speaker

Adam Gold, PhD

Medical Science Liasion

NS Pharma

See more from same speaker

Kevin Flanigan, MD

Director, Center for Gene Therapy Nationwide Children's Hospital

See more from same speaker

Karin Lucas, Ph.D

West Medical Science Liaison Team Lead, Global Medical Affairs Sarepta Therapeutics

See more from same speaker

Christian Werner, MD

Executive Director, Global Medical Affairs, and Global Duchenne Muscular Dystrophy Lead PTC Therapeutics

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years